Philip Storey, MD
Ophthalmology · Austin, TXNPI 1053614453
Payments from drug & device makers
Across 701 payments — averaging $3023.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1.1M
- Eyepoint US, Inc.$812K
- Regeneron Healthcare Solutions, Inc.$60K
- Genentech USA, Inc.$53K
- Baxter Healthcare$24K
- AbbVie$15K
- plus $20K from 17 others
Across 2 payments — averaging $1409.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 499 | $1,134,324 |
| Eyepoint US, Inc. | 7 | $811,989 |
| Regeneron Healthcare Solutions, Inc. | 53 | $60,435 |
| Genentech USA, Inc. | 50 | $53,380 |
| Baxter Healthcare | 24 | $24,230 |
| AbbVie | 11 | $15,184 |
| Apellis Pharmaceuticals, Inc. | 18 | $6,773 |
| Genentech, Inc. | 5 | $4,437 |
| Ocular Therapeutix, Inc. | 3 | $3,880 |
| F. Hoffmann-la Roche AG | 4 | $3,574 |
| Harrow Eye, LLC | 1 | $365 |
| Alimera Sciences, Inc. | 6 | $235 |
| Biotissue Holdings Inc. | 1 | $176 |
| Carl Zeiss Meditec, Inc. | 1 | $176 |
| Novartis | 2 | $165 |
| Astellas Pharma US Inc | 6 | $158 |
| Alcon | 2 | $142 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Bausch & Lomb Americas Inc. | 2 | $44 |
| Halozyme Inc | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Biogen | 1 | $14 |
How this compares
$2,119,796 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Saradha ChexalAustin$1.8M
- James DoonerAustin$556K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.